Cohance Lifesciences Limited has announced the appointment of Umang Vohra as Executive Chairman (effective May 1, 2026) and Group CEO (effective May 20, 2026), marking a key leadership transition as the company enters its next growth phase.
Vohra will succeed Vivek Sharma, who is stepping down from the role for personal reasons and will continue as an advisor for the next nine months to ensure a smooth transition.
The appointment reflects a strategic move by the board to bring in leadership aligned with the company’s transformation and expansion plans. Cohance has established a strong presence in the global CDMO space, with capabilities across complex chemistry, APIs, ADCs, oligonucleotides, and performance materials.
Vohra brings over three decades of experience in the pharmaceutical industry and most recently served as CEO and Managing Director of Cipla Limited, where he led the company’s transformation into a diversified global pharma player.
His appointment is expected to strengthen Cohance’s strategic direction, leveraging his expertise in scaling global businesses, driving operational excellence, and building customer-focused organizations.